Introduction {#s1}
============

MicroRNAs (miRNAs) are small, non-coding, endogenous RNAs that represent a significant mechanism of post transcriptional gene regulation [@pone.0039623-Babashah1]. It has been demonstrated that miRNAs have a crucial function in affecting processes as varied as cellular differentiation, proliferation, metabolism, apoptosis, and tumorigenesis [@pone.0039623-Cai1]. Several miRNA expression analyses in human epithelial malignancies have shown that distinct tumor specific miRNA signatures can distinguish different cancer types and classify their sub-types [@pone.0039623-Hui1]. Some of the key dysregulated miRNAs have the potential value to be molecular bio-markers, which can improve diagnosis, prognosis, and monitoring of treatment response for human cancers [@pone.0039623-Qu1]--[@pone.0039623-Ji1]. Some miRNAs may function as oncogenes or tumor suppressors [@pone.0039623-Kan1]--[@pone.0039623-Kano1].

Primary miRNA transcripts are cleaved by Ribonuclease (RNase) III Drosha in the cell nucleus into 70-nucleotide to 80-nucleotide precursor miRNA (pre-miRNA) hairpins and transported to the cytoplasm. Then, pre-miRNAs are processed by RNase III Dicer into miRNA: miRNA duplexes. One strand of these duplexes is generally degraded, whereas the other is used as mature miRNA. Mature miRNAs can recognize and bind into the 3′-untranslated region (UTR) of the target mRNAs and interfere with their translation [@pone.0039623-Bartel1]. It was hypothesized that single nucleotide polymorphisms (SNPs) within the miRNA sequence or miRNA target could either weaken or reinforce the binding between miRNA and target [@pone.0039623-Landi1].

In the human genome, miR-146a is located at chromosome 5q33. Many recent studies have suggested that miR-146a expression is deregulated in many solid tumors [@pone.0039623-Wang1]--[@pone.0039623-Yu1]. It became evident that miR-146a may act as a tumor suppressor. So far, the possible mechanism through which a miR-146a downmodulation may contribute to tumor development remains unclear. However, it seems related to the capacity of this miRNA to target some mRNAs [@pone.0039623-Labbaye1]. A G\>C polymorphism has been identified in the miR-146a gene, and the reference number of this SNP in the database of the National Center for Biotechnology information (NCBI) is rs2910164 [@pone.0039623-Hu1].This polymorphism exists in the stem region opposite to the mature miR-146a sequence, which leads to a change from G:U pair to C:U mismatch in the stem structure of miR-146a precursor [@pone.0039623-Hu1].A recent study provided evidence that the existence of a common G/C polymorphism within the pre-miR-146a sequence reduced production of miR-146a [@pone.0039623-Jazdzewski1]. This may lead to a reduced downmodulation of the corresponding target genes. Several studies have reported that this polymorphism could contribute to tumorigenesis of many cancers, especially those belonging to the gastrointestinal (GI) tract, such as gastric cancer and hepatocellular carcinoma [@pone.0039623-Peng1]--[@pone.0039623-Chen1].

The GI cancers share a number of characteristics that suggest common etiological pathways or mechanisms. Thus, the identification of possible risk factors and carcinogenetic mechanisms is essential for the prevention of these cancers. Accumulating evidence has uncovered the important role of inflammatory network in the promotion of GI cancer development [@pone.0039623-Oshima1]. Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) could lower the mortality rate from cancers in the gastrointestinal tract [@pone.0039623-Giovannucci1]. Environmental, dietary and endogenous risk factors are thought to exert important effects on individual predisposition [@pone.0039623-Landi1]. From 2008 to 2012, researchers have consecutively reported associations between miR-146a rs2910164 polymorphism and risk of GI cancers, but with mixed or even conflicting results [@pone.0039623-Xiang1]--[@pone.0039623-Ye1]. Accordingly, we aimed to conduct a meta-analysis to shed more light on the role of miR-146a rs2910164 polymorphism in susceptibility to GI cancers.

Materials and Methods {#s2}
=====================

Identification of Eligible Studies {#s2a}
----------------------------------

We performed a systematic search using Pubmed, Excerpta Medica Database (Embase) and Chinese Biomedical Literature Database (CBM) with the last search updated on February 24, 2012. The following search terms were used: "microRNA OR mir OR miRNA", "cancer OR carcinoma OR adenocarcinoma OR neoplasm OR tumour OR tumor", "gene OR polymorphism OR allele OR variation", and "146a OR rs2910164". Searching was done without restriction on language or publication years. We evaluated all associated publications to retrieve the most eligible literature. Their reference lists were searched manually to identify additional eligible studies.

Inclusion and Exclusion Criteria {#s2b}
--------------------------------

The following inclusion criteria were used in selecting literature for further meta-analysis: (1) evaluation of miR-146a rs2910164 polymorphism and GI cancers; (2) independent case-control studies for human; (3) describing useful genotype frequencies; (4) only full-text manuscripts were included. Exclusion criteria included: (1) duplication of the previous publications; (2) abstract, comment, review and editorial; (3) family-based studies of pedigrees with several affected cases per family. When a study reported the results on different ethnicities, we treated them as separate studies. When there were multiple publications from the same population, only the largest study was included.

Data Extraction {#s2c}
---------------

Two investigators independently extracted the data according to the inclusion criteria listed above. Discrepancies were adjudicated by a third investigator until consensus was achieved on every item. The following information was extracted from each eligible study using a standardized data collection protocol (the PRISMA checklist, [Table S1](#pone.0039623.s001){ref-type="supplementary-material"}): the first author's name, year of publication, source of publication, ethnicity, cancer types, definition and numbers of cases and controls, and allele as well as genotype frequencies for cases and controls. If original genotype frequency data was unavailable in relevant articles, a request for additional data was sent to the corresponding author.

Quality Score Assessment {#s2d}
------------------------

The quality of the studies was independently assessed by two investigators according to a set of predetermined criteria which was extracted and modified from previous studies [@pone.0039623-Jiang1]--[@pone.0039623-Zou1] ([Table 1](#pone-0039623-t001){ref-type="table"}). These scores were based on traditional epidemiological considerations, as well as cancer genetic issues. Any disagreement was resolved by discussion between the two investigators. Scores ranged from the lowest zero to the highest 18. Articles scoring \<12 were classified as "low quality", and those ≥12 as "high quality".

10.1371/journal.pone.0039623.t001

###### Scale for quality assessment.

![](pone.0039623.t001){#pone-0039623-t001-1}

  Criterion                                                    Score
  ----------------------------------------------------------- -------
  *Source of cases*                                           
  Selected from population or cancer registry                    3
  Selected from hospital                                         2
  Selected from pathology archives, but without description      1
  Not described                                                  0
  *Source of controls*                                        
  Population-based                                               3
  Blood donors or volunteers                                     2
  Hospital-based (cancer-free patients)                          1
  Not described                                                  0
  *Case-control match*                                        
  Matched by age and gender                                      3
  Not matched by age and gender                                  0
  *Specimens used for determining genotypes*                  
  White blood cells or normal tissues                            3
  Tumor tissues or exfoliated cells of tissue                    0
  *Hardy-Weinberg equilibrium in controls*                    
  Hardy-Weinberg equilibrium                                     3
  Hardy-Weinberg disequilibrium                                  0
  *Total sample size*                                         
  \>1000                                                         3
  \>500 and \<1000                                               2
  \>200 and \<500                                                1
  \<200                                                          0

Meta-analysis Methods {#s2e}
---------------------

We used the PRISMA checklist as protocol of the meta-analysis and followed the guideline ([Table S1](#pone.0039623.s001){ref-type="supplementary-material"}) [@pone.0039623-Moher1]. We first assessed Hardy-Weinberg equilibrium for each study using Chi-square test in control groups. The odds ratio (OR) and its 95% confidence interval (95%CI) were used to assess the strength of the association between miR-146a rs2910164 polymorphism and risk of GI cancers based on genotype frequencies in cases and controls. The pooled ORs were performed for allelic comparison (G versus C), dominant model (GG + GC versus CC), recessive model (GG versus GC+CC), homozygote comparison (GG versus CC) and heterozygote comparison (GC versus CC), respectively. The significance of the pooled OR was determined by the *Z*-test. Stratified analyses were performed by ethnicity, cancer types and quality of studies. A Chi-square test based Q-statistic was performed to assess the between-study heterogeneity [@pone.0039623-Cochran1]. If the heterogeneity was not significant, the fixed effect model (using the Mantel-Haenszel method) was used to estimate the summary OR and 95% CI; otherwise, the random effect model (using the DerSimonian and Laird method) was used [@pone.0039623-Mantel1]--[@pone.0039623-DerSimonian1]. We also measured the effect of heterogeneity by another measure, *I^2^* = 100%×(Q-df)/Q [@pone.0039623-Higgins1].

Evaluation of Publication Bias {#s2f}
------------------------------

Potential publication bias was estimated using Egger's linear regression test (*P*\<0.05 was considered significant) by visual inspection of the funnel plot [@pone.0039623-Egger1]. Analyses were performed using the software Review Manager 4.2 (Cochrane Collaboration, <http://www.cc-ims.net/RevMan/relnotes.htm/>) and Stata version 10 (StataCorp LP, College Station, Texas, USA). The pooled ORs were performed for allelic comparison, dominant model, recessive model, homozygote comparison and heterozygote comparison, respectively. Thus, the Bonferroni method was used to adjust the significance alpha level to correct for the problem of multiple comparisons. Specifically, the usual significance level (α = 0.05) was divided by 5 to account for five comparisons. Thus, a *P* value less than 0.01 was considered statistically significant in the study, and all the *P* values were two sided.

Results {#s3}
=======

Characteristics of Eligible Studies ([Table 2](#pone-0039623-t002){ref-type="table"}) {#s3a}
-------------------------------------------------------------------------------------

Main characteristics of the included publications investigating the association of miR-146a rs2910164 polymorphism with GI cancers are presented in [Table 2](#pone-0039623-t002){ref-type="table"}. There were 308 articles relevant to the searching words (Pubmed:98; Embase:199; CBM:11). The flow chart in [Figure 1](#pone-0039623-g001){ref-type="fig"} summarizes this literature review process. In the current study, a total of 12 eligible studies (4,817 cases and 5,389 controls) met the inclusion criteria [@pone.0039623-Xiang1]--[@pone.0039623-Ye1].

10.1371/journal.pone.0039623.t002

###### Characteristics of studies included in the meta-analysis.[\*](#nt101){ref-type="table-fn"}

![](pone.0039623.t002){#pone-0039623-t002-2}

  ID                        Study                       Year   Ethnic group      Cancer type       Sample size   *P* for HWE   Quality score  
  ---- ----------------------------------------------- ------ -------------- -------------------- ------------- ------------- --------------- ----
  1          Xiang et al. [@pone.0039623-Xiang1]        2012      Asian          Liver cancer          100           100           0.506       10
  2            Min et al. [@pone.0039623-Min1]          2011      Asian       Colorectal cancer        446           502           0.443       14
  3           Zhou et al. [@pone.0039623-Zhou1]         2011      Asian          Liver cancer          186           483           0.056       14
  4          Akkız et al. [@pone.0039623-Akkz1]         2011    Caucasian        Liver cancer          222           222           0.384       13
  5          Zhang et al. [@pone.0039623-Zhang1]        2011      Asian          Liver cancer          963           852           0.149       17
  6          Okubo et al. [@pone.0039623-Okubo1]        2010      Asian         Gastric cancer         552           697         \<0.0001      9
  7        Hishida et al. [@pone.0039623-Hishida1]      2010      Asian         Gastric cancer         583           699           0.337       15
  8            Guo et al. [@pone.0039623-Guo1]          2010      Asian       Esophageal cancer        444           468           0.120       14
  9           Zeng et al. [@pone.0039623-Zeng1]         2010      Asian         Gastric cancer         304           304           0.122       14
  10    Srivastava et al. [@pone.0039623-Srivastava1]   2010      Asian       Gallbladder cancer       230           230           0.080       15
  11            Xu et al. [@pone.0039623-Xu1]           2008      Asian          Liver cancer          479           504           0.119       14
  12            Ye et al. [@pone.0039623-Ye1]           2008    Caucasian     Esophageal cancer        346           346            NA         12

HWE, Hardy-Weinberg equilibrium; NA, not available.

![The flow chart of the included studies in the meta-analysis.](pone.0039623.g001){#pone-0039623-g001}

Among the 12 publications, five studies focused on liver cancer [@pone.0039623-Xiang1], [@pone.0039623-Zhou1]--[@pone.0039623-Zhang1], [@pone.0039623-Xu1], three studies on gastric cancer [@pone.0039623-Okubo1], [@pone.0039623-Hishida1], [@pone.0039623-Zeng1], two studies on esophageal cancer [@pone.0039623-Guo1], [@pone.0039623-Ye1], one study on colorectal cancer [@pone.0039623-Min1] and one study on gallbladder cancer [@pone.0039623-Srivastava1], respectively. Of all studies, ten studies were conducted in Asian populations [@pone.0039623-Xiang1]--[@pone.0039623-Zhou1], [@pone.0039623-Zhang1]--[@pone.0039623-Xu1], and two in Caucasian populations [@pone.0039623-Akkz1], [@pone.0039623-Ye1]. The results of Hardy-Weinberg equilibrium test for the distribution of the genotype in control population are shown in [Table 2](#pone-0039623-t002){ref-type="table"}. The genotype frequency distributions of controls in 10 of 12 studies were in agreement with HWE. We could not perform the Hardy-Weinberg equilibrium test for one study, because only the data of allele frequency was available [@pone.0039623-Ye1]. Thus, for quality assessment, this study was considered as Hardy-Weinberg disequilibrium. Quality scores for the individual studies ranged from 9 to 17, with 83% (10 of 12) of the studies being classified as high quality (≥12).

Association between miR-146a rs2910164 Polymorphism and GI Cancers {#s3b}
------------------------------------------------------------------

The summary of the meta-analysis for miR-196a2 rs11614913 polymorphism and GI cancers is shown in [Table 3](#pone-0039623-t003){ref-type="table"}. We first analyzed the association in the overall population. Then in order to obtain the exact consequence of the relationship between miR-146a rs2910164 polymorphism and GI cancers susceptibility, stratified analyses by ethnicity, cancer types and quality of studies were performed. When the Q-test of heterogeneity was not significant, we conducted analyses using the fixed effect models. The random effect models were conducted when we detected significant between-study heterogeneity.

10.1371/journal.pone.0039623.t003

###### Meta-analysis of miR-146a rs2910164 polymorphism with gastrointestinal cancers.[\*](#nt102){ref-type="table-fn"}

![](pone.0039623.t003){#pone-0039623-t003-3}

  Comparisons          Sample size   No. of Studies   Test of association   Test of heterogeneity                                                            
  ------------------- ------------- ---------------- --------------------- ----------------------- ------------------- -------- -------- --- ------- ------- ------
  Overall                G vs C           9634               10778                   12             1.07(0.98--1.16)     1.46     0.14    R   21.64   0.03    49.2
                       GG+GC vs CC        4471               5043                    11             1.14(1.00--1.31)     1.94     0.05    R   18.23   0.05    45.1
                       GG vs GC+CC        4471               5043                    11             1.06(0.91--1.23)     0.72     0.47    R   20.47   0.03    51.2
                        GG vs CC          2394               2767                    11             1.17 (0.95--1.44)    1.50     0.13    R   21.91   0.02    54.4
                        GC vs CC          3396               3915                    11             1.14(1.00--1.31)     1.92     0.05    R   16.25   0.09    38.5
  Asian                  G vs C           8498               9642                    10             1.09(0.99--1.19)     1.70     0.09    R   19.87   0.02    54.7
                       GG+GC vs CC        4249               4821                    10             1.15(0.99--1.32)     1.88     0.06    R   18.22   0.03    50.6
                       GG vs GC+CC        4249               4821                    10             1.08(0.91--1.27)     0.89     0.37    R   19.50   0.02    53.9
                        GG vs CC          2247               2612                    10             1.18(0.95--1.47)     1.48     0.14    R   21.88   0.009   58.9
                        GC vs CC          3311               3837                    10             1.14(0.99--1.31)     1.82     0.07    R   16.22   0.06    44.5
  Caucasian              G vs C           1136               1136                     2             0.94(0.77--1.14)     0.65     0.51    F   0.02    0.90    0.0
  Liver cancer           G vs C           3824               4298                     5             1.07(0.98--1.18)     1.50     0.13    F   5.83    0.21    31.4
                       GG+GC vs CC        1912               2149                     5             1.11(0.96--1.27)     1.44     0.15    F   3.69    0.45    0.0
                       GG vs GC+CC        1912               2149                     5             1.08(0.92--1.27)     0.95     0.34    F   7.33    0.12    45.4
                        GG vs CC          1015               1147                     5             1.18 (0.97--1.43)    1.65     0.10    F   5.76    0.22    30.6
                        GC vs CC          1479               1704                     5             1.09(0.94--1.26)     1.10     0.27    F   3.28    0.51    0.0
  Gastric cancer         G vs C           2878               3400                     3             1.05(0.89--1.24)     0.62     0.54    R   4.99    0.08    59.9
                       GG+GC vs CC        1439               1700                     3             1.15(0.88--1.51)     1.01     0.31    R   6.72    0.03    70.3
                       GG vs GC+CC        1439               1700                     3             0.93(0.77--1.13)     0.71     0.48    F   4.41    0.11    54.7
                        GG vs CC          772                 972                     3             1.04(0.74--1.47)     0.25     0.81    R   4.98    0.08    59.9
                        GC vs CC          1222               1430                     3             1.20(0.88--1.64)     1.13     0.26    R   7.77    0.02    74.3
  Esophageal cancer      G vs C           1580               1628                     2             1.15(0.80--1.66)     0.74     0.46    R   5.26    0.02    81.0
  High quality           G vs C           8330               9184                    10             1.07(0.97--1.18)     1.31     0.19    R   20.13   0.02    55.3
                       GG+GC vs CC        3819               4246                     9             1.14(0.96--1.35)     1.52     0.13    R   18.03   0.02    55.6
                       GG vs GC+CC        3819               4246                     9             1.09(0.94--1.27)     1.15     0.25    R   13.95   0.08    42.6
                        GG vs CC          2030               2270                     9             1.22(0.97--1.53)     1.67     0.09    R   17.51   0.03    54.3
                        GC vs CC          2844               3260                     9             1.12(0.95--1.31)     1.35     0.18    R   14.70   0.07    45.6
  Low quality            G vs C           1304               1594                     2             1.02(0.88--1.19)     0.26     0.79    F   1.18    0.28    15.1
                       GG+GC vs CC        652                 797                     2             1.16(0.94--1.44)     1.41    0\. 61   F   0.09    0.77    0.0
                       GG vs GC+CC        652                 797                     2             0.94(0.50--1.76)    0\. 19   0\. 85   R   3.10    0.08    67.7
                        GG vs CC          364                 497                     2             0.91(0.67--1.23)     0.61     0.54    F   2.07    0.15    51.7
                        GC vs CC          552                 655                     2             1.29(1.02--1.61)     2.16     0.03    F   0.12    0.73    0.0

OR, odds ratio; vs, versus; R, random effect model; F, fixed effect model.

Overall, when all types of GI cancers were considered together in the meta-analysis, there was no evidence of association between miR-146a rs2910164 polymorphism and the risk of GI cancers in any genetic model (G versus C: OR = 1.07, 95%CI 0.98−1.16, *P* = 0.14; GG+GC versus CC: OR = 1.14, 95%CI 1.00−1.31, *P* = 0.05; GG versus GC+CC: OR = 1.06, 95%CI 0.91−1.23, *P* = 0.47; GG versus CC: OR = 1.17, 95%CI 0.95−1.44, *P* = 0.13; GC versus CC: OR = 1.14, 95%CI 1.00−1.31, *P* = 0.05).

Next, we performed subgroup analyses according to ethnicity of the studies. In Asians, no significant association between miR-146a rs2910164 polymorphism and the risk of GI cancers was found for all genetic model (G versus C: OR = 1.09, 95%CI 0.99−1.19, *P* = 0.09; GG+GC versus CC: OR = 1.15, 95%CI 0.99−1.32, *P* = 0.06; GG versus GC+CC: OR = 1.08, 95%CI 0.91−1.27, *P* = 0.37; GG versus CC: OR = 1.18, 95%CI 0.95−1.47, *P* = 0.14; GC versus CC: OR = 1.14, 95%CI 0.99−1.31, *P* = 0.07). In Caucasians, there was no evidence of association between the variant genotypes of miR-146a rs2910164 polymorphism and the risk of GI cancers in the allelic comparison (G versus C: OR = 0.94, 95%CI 0.77−1.14, *P* = 0.51).

Moreover, we investigated the effect of the miR-146a rs2910164 polymorphism on the susceptibility to subtypes of GI cancers. No evidence of association was observed in any genetic model between miR-146a rs2910164 polymorphism and risk of liver cancer (G versus C: OR = 1.07, 95%CI 0.98−1.18, *P* = 0.13; GG+GC versus CC: OR = 1.11, 95%CI 0.96−1.27, *P* = 0.15; GG versus GC+CC: OR = 1.08, 95%CI 0.92−1.27, *P* = 0.34; GG versus CC: OR = 1.18, 95%CI 0.97−1.43, *P* = 0.10; GC versus CC: OR = 1.09, 95%CI 0.94−1.26, *P* = 0.27), gastric cancer (G versus C: OR = 1.05, 95%CI 0.89−1.24, *P* = 0.54; GG+GC versus CC: OR = 1.15, 95%CI 0.88−1.51, *P* = 0.31; GG versus GC+CC: OR = 0.93, 95%CI 0.77−1.13, *P* = 0.48; GG versus CC: OR = 1.04, 95%CI 0.74−1.47, *P* = 0.81; GC versus CC: OR = 1.20, 95%CI 0.88−1.64, *P* = 0.26) and esophageal cancer (G versus C: OR = 1.15, 95%CI 0.80−1.66, *P* = 0.46).

We also performed subgroup analysis according to quality of studies. In the subgroup of high quality studies, no significant association between miR-146a rs2910164 polymorphism and risk of GI cancers was observed (G versus C: OR = 1.07, 95%CI 0.97−1.18, *P* = 0.19; GG+GC versus CC: OR = 1.14, 95%CI 0.96−1.35, *P* = 0.13; GG versus GC+CC: OR = 1.09, 95%CI 0.94−1.27, *P* = 0.25; GG versus CC: OR = 1.22, 95%CI 0.97−1.53, *P* = 0.09; GC versus CC: OR = 1.12, 95%CI 0.95−1.31, *P* = 0.18). In the subgroup of low quality studies, there was also no evidence of association between miR-146a rs2910164 polymorphism and the risk of GI cancers in any genetic model (G versus C: OR = 1.02, 95%CI 0.88−1.19, *P* = 0.79; GG+GC versus CC: OR = 1.16, 95%CI 0.94−1.44, *P* = 0.61; GG versus GC+CC: OR = 0.94, 95%CI 0.50−1.76, *P* = 0.85; GG versus CC: OR = 0.91, 95%CI 0.67−1.23, *P* = 0.54; GC versus CC: OR = 1.29, 95%CI 1.02−1.61, *P* = 0.03).

Evaluation of Publication Bias ([Table 4](#pone-0039623-t004){ref-type="table"}) {#s3c}
--------------------------------------------------------------------------------

The results of Egger's linear regression test are shown in [Table 4](#pone-0039623-t004){ref-type="table"}. The shape of the funnel plots did not reveal any evidence of obvious asymmetry for all genetic models in the overall meta-analysis. Egger's test was used to provide statistical evidence of funnel plot symmetry. The intercept *a* provides a measure of asymmetry, and the larger its deviation from zero the more pronounced the asymmetry. The results still did not present any obvious evidence of publication bias for any of the genetic models. Egger's test only detected evidence of publication bias in the subgroup analysis of gastric cancer for allelic contrast (P = 0.004). However, Egger's test was not applied in some comparisons due to the small number of studies.

10.1371/journal.pone.0039623.t004

###### Egger's linear regression test to measure the funnel plot asymmetric.[\*](#nt103){ref-type="table-fn"}

![](pone.0039623.t004){#pone-0039623-t004-4}

  Groups            Y axis intercept: *a (95%CI)*                                                                     
  ---------------- ------------------------------- --------------------- ---------------------- --------------------- ---------------------
  Overall                 0.02 (−3.33−3.37)          0.29(−2.02−2.60)       0.80(−3.57−5.17)      0.75(−2.24−3.74)      0.02(−2.19−2.23)
  Asian                   0.85(−3.34−5.05)           0.40(−2.47−3.28)       1.07(−3.59−5.72)      1.06(−2.58−4.70)     −0.06(−2.81--2.70)
  Liver cancer            0.24(−5.20−5.67)           −0.01(−3.56−3.55)      2.18(−4.03−8.38)      0.90(−3.81−5.60)     −0.20 (−3.53−3.13)
  Gastric cancer          8.70(7.98--9.43)          7.20(−53.24--67.63)   7.63(−88.45--103.70)   9.47(−18.33--37.26)   6.26(−80.96--93.49)
  High quality           −0.81(−5.23--3.61)          0.25(−2.78--3.26)     −0.09(−5.72--5.54)     0.25(−3.33--3.84)     0.16(−2.60--2.91)

vs, versus.

Discussion {#s4}
==========

In the present meta-analysis with 4,817 cases and 5,389 controls, there was no evidence of association between miR-146a rs2910164 polymorphism and the risk of GI cancers. Similar results were found in the subgroup analyses by ethnicity, cancer types, and quality of studies. The current study is the largest meta-analysis of the association between miR-146a rs2910164 polymorphism and the risk of GI cancers.

In 2011, several meta-analyses were conducted to investigate the association between miR-146a rs2910164 polymorphism and overall cancer risk. Xu et al. [@pone.0039623-Xu2] and Qiu et al. [@pone.0039623-Qiu1] both identified that miR-146a rs2910164 polymorphism was not associated with overall cancer risk. In another meta-analysis, overall increased cancer risk was only found in dominant model (*P* = 0.02) [@pone.0039623-Wang2]. Nevertheless, the authors did not adjust the significance alpha level. If multiple comparisons were corrected, a negative result would be obtained. In consistent with these reports, we did not find any association between miR-146a rs2910164 polymorphism and the risk of GI cancers in overall analysis. When stratified by cancer types, Xu et al. [@pone.0039623-Xu2] found that the C allele of miR-146a rs2910164 polymorphism might be associated with protection from digestive cancer in subgroup analysis. But the subgroup analysis only included three studies [@pone.0039623-Guo1], [@pone.0039623-Srivastava1], [@pone.0039623-Xu1]. Contrary to the result, our meta-analysis provided more sufficient evidence that miR-146a rs2910164 was not a functional polymorphism on GI cancers susceptibility based on larger sample sizes and increased statistical power. Similarly, in subgroup analysis, we consistently showed no association between this SNP and GI cancers.

The current meta-analysis is based on a single polymorphism strategy to explore the association between miR-146a gene polymorphism and GI cancers. Duan and colleagues have identified 323 SNPs in 227 human known miRNAs [@pone.0039623-Duan1]. Though a single SNP has limited effect on the risk of GI cancers, interactions of multiple SNPs in miRNA-related genes might augment the effect. Development of GI cancers is a multistage process, and a single polymorphism might have a limited impact on GI cancers susceptibility [@pone.0039623-Landi1]. More comprehensive haplotype-based or multiple polymorphisms-based strategies rather than a single polymorphism-based strategy are warranted, which may provide more precise information on genetic contribution of miR-146a gene polymorphism to GI cancers etiology. In addition to genetic predisposition, environmental exposure, such as smoking, alcohol consumption, and diet, is also thought to play a crucial role in the etiology of GI cancers [@pone.0039623-Yu2]. Gene-environment interactions should be considered in further studies if individual data of environmental exposure are available.

Certain potential limitations exist in our meta-analysis. Firstly, the controls for one study included in this meta-analysis were not in Hardy-Weinberg equilibrium. To some extent, the results of genetic association studies might be distorted. Secondly, publication bias was detected in the subgroup analysis of gastric cancer for allelic contrast. This may also distort the meta-analysis. Thirdly, as with most meta-analyses, results should be interpreted with caution because of obvious between-study heterogeneity in some comparisons. Fourthly, if individual data were available, we could perform a more precise analysis with an adjustment estimate. Finally, colorectal cancer is the commonest cancer of the alimentary tract. Lacking sufficient eligible studies on colorectal cancer limited our further stratified analyses.

In conclusion, results from meta-analysis of published data show that miR-146a rs2910164 polymorphism is not associated with GI cancers susceptibility. It is necessary to conduct more well-designed studies based on larger sample sizes and homogeneous cancer patients.
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